In a mouse model, lenvatinib significantly decreased the population of tumor-associated macrophages (TAMs) and increased the percentages of CD8-positive T cells, which led to enhanced antitumor activity by PD-1 inhibitors [93]. The gene discussed is CD8A; the disease is neoplasm.